Autologous Blood Transfusion Clinical Trial
Official title:
Department of Anesthesiology, Beijing Anzhen Hospital, Capital Medical University
Perioperative blood loss continues to be a serious problem in complex aortic arch surgery
using deep hypothermic circulatory arrest (DHCA). Major blood loss causes increased
morbidity and mortality [1]. These patients often require transfusion of allogeneic blood
products. It has been estimated shortages of blood supply in China will worsen [2].
Clinicians have made significant progress to decrease the quality of allogenic blood
transfusion.
Increasing postoperative hemorrhage risk of aortic arch patients undergoing DHCA may be
related to CPB induced hemostatic defect, the use of the CPB is likely to contribute to
coagulation factor lost and platelet dysfunction [3, 4]. We are aware of the potential
benefit of aPRP, withdrawal of aPRP immediately before initiating CPB appears to be a
promising approach because it avoids CPB-related platelet damage and limits post-CPB blood
loss. So we adopted and used aPRP as a blood conservation technique to reduce blood
transfusion in aortic arch surgery with DHCA. Autologous red blood cells were infused to
maintain a HGB level above 100 g/L after heparin neutralizing activity. And aPRPs were
transfused after heparin neutralizing activity as no active bleeding was observed. Our goal
was to determine the effect between aPRP and homologous transfusion on perioperative
bleeding during complex aortic arch surgery using DHCA.
Status | Temporarily not available |
Enrollment | 0 |
Est. completion date | |
Est. primary completion date | June 2015 |
Accepts healthy volunteers | |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - adults older than 18 years old, type A aortic dissections patients undergoing frozen elephant trunk with total arch replacement (Bentall plus Sun's surgery) with DHCA. Exclusion Criteria: - patients with hepatitis B virus infection, coagulation disorder, anemia (HBG<11mg/dl), stopping anticoagulants less than 7 days and end-stage renal disease dependent on hemodialysis. |
N/A
Country | Name | City | State |
---|---|---|---|
China | Beijing Anzhen Hospital | Beijing | Beijing |
Lead Sponsor | Collaborator |
---|---|
Beijing Anzhen Hospital |
China,
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04496700 -
Transfusion of Whole Blood to Military Forces in a Combat Situation
|
N/A | |
Not yet recruiting |
NCT06244264 -
The Safety and Efficacy of Autologous Transfusion in Spinal Surgery for Lung Cancer With Spinal Metastasis
|
N/A | |
Completed |
NCT05539846 -
Explore the Feasibility of Modified Blood Collection Method
|
N/A |